Definium Therapeutics (DFTX) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $4.4B
- As of Nov 13, 2026
- P/E
- -13.01x
- Trailing twelve months
- P/B
- 4.54x
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- -34.9%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $4.4B
- As of Nov 13, 2026
- P/E
- -13.01x
- Trailing twelve months
- P/B
- 4.54x
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- -34.9%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-13.01x
Net loss — not comparable
P/B
4.54x
P/S
—
Earnings and dividend metrics▾
Earnings
EPS
-$2.47
Earnings per share
BPS
$7.07
Book value per share
ROE
-34.9%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $2.47 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $7.07 of net assets.
- ROE — shareholder equity shrank by 34.9% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Operating income decreased from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Operating income · same quarter, three years
Year-ago quarter -$46MDown
-$25M
Jul–Sep '24
-$46M
Jul–Sep '25
-$72M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 9, 2026.
- Earnings per share increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Operating income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Nov 9, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Barrow RobertChief Executive Officer · Sep 25, 2026Open-market sale31,550 shares · $1.2MAvg. price $36.572,213,090 shares held after
- Sullivan MarkChief Legal Officer · Sep 25, 2026Open-market sale14,051 shares · $514KAvg. price $36.57494,228 shares held after
- Karlin DanielChief Medical Officer · Sep 25, 2026Open-market sale10,853 shares · $397KAvg. price $36.57792,846 shares held after
- Roberts BrandiChief Financial Officer · Sep 25, 2026Open-market sale3,377 shares · $123KAvg. price $36.57394,528 shares held after
- Wiley Matthew T.Chief Commercial Officer · Sep 25, 2026Open-market sale3,097 shares · $113KAvg. price $36.57359,036 shares held after
- Krebs AndreasDirector · Sep 18, 2026Option exercise1,629 shares · $58KAvg. price $35.5221,402 shares held after
- Vallone Carol ADirector · Sep 18, 2026Option exercise1,086 shares · $39KAvg. price $35.5222,296 shares held after
- Roberts BrandiChief Financial Officer · Sep 14, 2026Grant or award125,000 shares · $0Avg. price $0397,905 shares held after
- Barrow RobertChief Executive Officer · Sep 14, 2026Grant or award750,000 shares · $0Avg. price $02,244,640 shares held after
- Karlin DanielChief Medical Officer · Sep 14, 2026Grant or award200,000 shares · $0Avg. price $0803,699 shares held after
- Wiley Matthew T.Chief Commercial Officer · Sep 14, 2026Grant or award125,000 shares · $0Avg. price $0362,133 shares held after
- Sullivan MarkChief Legal Officer · Sep 14, 2026Grant or award125,000 shares · $0Avg. price $0508,279 shares held after
- Barrow RobertChief Executive Officer · Sep 3, 2026Open-market sale19,023 shares · $722KAvg. price $37.941,494,640 shares held after
- Barrow RobertChief Executive Officer · Sep 2, 2026Grant or award40,000 shares · $0Avg. price $01,513,663 shares held after
- Barrow RobertChief Executive Officer · Aug 12, 2026Grant or award375,000 shares · $0Avg. price $01,473,246 shares held after
- Roberts BrandiChief Financial Officer · Aug 12, 2026Grant or award62,500 shares · $0Avg. price $0271,987 shares held after
- Wiley Matthew T.Chief Commercial Officer · Aug 12, 2026Grant or award62,500 shares · $0Avg. price $0237,133 shares held after
- Sullivan MarkChief Legal Officer · Aug 12, 2026Grant or award62,500 shares · $0Avg. price $0383,071 shares held after
- Karlin DanielChief Medical Officer · Aug 12, 2026Grant or award100,000 shares · $0Avg. price $0603,282 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Definium Therapeutics (DFTX) stock information
NASDAQ
Definium Therapeutics (DFTX) is listed on NASDAQ. Its market capitalization is about $4.4B. On trailing-twelve-month earnings the P/E ratio is -13.01, and the P/B ratio is 4.54. Return on equity is -34.9%. These figures are computed in-house from official filings and are reference information only.
Definium Therapeutics — frequently asked questions
- What is the P/E ratio of Definium Therapeutics (DFTX)?
- On a trailing-twelve-month basis, DFTX trades at a P/E ratio of -13.01. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Definium Therapeutics?
- DFTX has a market capitalization of about $4.4B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.